Is less actually more when trying to liberate patients with AKI on dialysis? Read the summary 10 posts and find out
BigPAK or a bundle of balderdash?
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
TenPosts PISCES
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
Attacking the Origin of IgAN: ORIGIN3 and Atacicept
ORIGIN-3: The Visual Abstract
ORIGIN-3: El Resumen Visual
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber
Kidney transplant diaries: achieving immune tolerance by chimerism
A thread on the most relevant part of the chat on tolerance induction in HLA-matched transplant with donor hematopoietic stem cells (MDR-101). Thread by Akshaya Jayachandran.
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
ASIs Advance: NephJC Shorts on BaxHTN
NephJC Shorts: ALCHEMIST trial and Meta-analysis
In ESRD is spironolactone an overACHIEVEr?
The ACHIEVE visual abstract
Does spironolactone decrease cardiovascular disease and heart failure hospitalizations in patients on dialysis?
Check out this crisp VA by Dr Akshaya Jayachandran.
NephJC Shorts: The end of the Fluid Wars?
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
CONFIDENCE Visual Abstract
Check out the beautiful visual abstract made by NephJC intern Michelle Fravel.
